Dutch telehealth company MyTomorrows has partnered with multi-stakeholder pressure group Pancreatic Cancer Europe to drive access to novel treatments across the continent by way of the company’s clinical trials database.
The new partnership will see Pancreatic Cancer Europe using the company’s database of ongoing clinical trials to equip patients, caregivers, and healthcare professionals with up-to-date information about pre-approval treatments that may be relevant to them.
Research published by the European Commission found that in 2020 pancreatic cancer accounted for 3.5% of all new cancer diagnoses and 7.1% of all deaths due to cancer, making it the seventh most frequently occurring cancer and the fourth leading cause of cancer death after lung.
MyTomorrows says that it aims for the partnership to ease the process of identifying and understanding the existing clinical trial options a patient may have, through a new clinical trial search tool.
MyTomorrows CEO Michel van Harten said: “We are very excited to be partnering with Pancreatic Cancer Europe, an organisation that works tirelessly to raise awareness of pancreatic cancer, promote advancements in treatments, and empower European member organisations to better address the relevant issues regarding the disease.
“Collaborating with leading patient advocacy groups like Pancreatic Cancer Europe helps us extend our reach to more patients in need and empower them to navigate their treatment journeys with more confidence and knowledge while enabling pharmaceutical companies to expand access throughout the drug development cycle.”
The announcement came after the European Medicines Agency (EMA) launched its own Clinical Trials Information System (CTIS) in July after an update to transparency rules removed the ability for sponsors to defer trial data for seven years.
Alfredo Carrato, chair of Pancreatic Cancer Europe, said: “The innovative myTomorrows platform will support patients suffering from pancreatic cancer, their caregivers and their treating physicians by significantly easing the process of accessing and navigating clinical trials, another opportunity for them, enabling a more informed and proactive approach to the treatment of this devastating disease.”
Elsewhere in the field of pancreatic cancer trials, a Phase III trial of RenovoRx’s drug-device combination therapy designed to treat locally advanced pancreatic cancer has seen another site enrolled on the TIGeR-PaC study.
